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Abstract
Background: Evidence suggests a relationship between human immunodeficiency virus (HIV) infection and chronic
obstructive pulmonary disease (COPD). Although the high burden of COPD and the HIV disease is clearly
demonstrated, to the best of our knowledge, there is a lack of summary and meta-analysis data on the
epidemiology of COPD in the global HIV-infected population to date. The present protocol for a systematic review
and meta-analysis intends to summarize existing data on the prevalence, incidence, and risk factors of COPD in the
global HIV-infected population.
Methods and design: The present review will include cohort, cross-sectional, and case-control studies conducted
among HIV infected people, which report prevalence, incidence, and factors associated with COPD or enough data
for their estimation. We will consider published and unpublished studies in English and French language, regardless
of geographical location. Relevant records will be searched using PubMed/Medline, and Scopus from inception to
December 31st, 2016. Reference lists of eligible papers and relevant review articles will be screened. Two
investigators will independently screen, select studies, and extract data, with discrepancies resolved by consensus or
arbitrarily by a third investigator. Risk of bias and methodological quality of the included studies will be assessed
using the Newcastle-Ottawa Scale. Funnel-plots and Egger’s test will be used to determine publication bias. The
study-specific estimates will be pooled through a random-effects meta-analysis model to obtain an overall
summary estimate. To keep the effect of studies with extremely small or extremely large estimates on the overall
estimate to a minimum, the variance of the study-specific prevalence/incidence will be stabilized with the Freeman-
Tukey single arc-sine transformation. The heterogeneity will be evaluated by the χ2 test on Cochrane’s Q statistic.
Results will be presented by geographic region and by antiretroviral therapy status. We plan to summarize data on
factors associated with COPD in narrative format.
Discussion: This systematic review and meta-analysis will give an overview of the epidemiology of COPD in the
global HIV population to inform policy-makers and to provide accurate data that can underpin effective
interventions for optimizing their detection and management.
Systematic review registration: PROSPERO CRD42016052639.
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Background
Chronic obstructive pulmonary disease (COPD) is a major
public health concern. This non-communicable chronic
disease is projected to be the fifth in terms of disease bur-
den by 2030 [1]. This preventable and non-curable disease
is usually associated with chronic inflammatory responses
in the airways, and the lung noxious particles or gases. It
is characterized by persistent and progressive airflow limi-
tation [1]. There are two mechanisms involved in the oc-
currence of COPD: small pulmonary airways disease
(obstructive bronchiolitis) and parenchymal destruction
(emphysema). The degree of mixture of these two mecha-
nisms depends on each individual [1].
Globally, the total number of estimated COPD related
deaths was about 3 million in 2015 (5% of total deaths glo-
bally) [2]. The primary cause of COPD is tobacco con-
sumption (including second hand smokers and passive
exposure) [1, 2], but evidence suggests a relationship to
human immunodeficiency virus (HIV) infection [3–8].
Globally, in 2030, HIV disease is projected to be the third
cause of death followed by COPD that takes the fourth
place [9]. At the end of 2015, there were 37 million people
living with HIV worldwide among which 1.1 million of
HIV-related deaths being notified [10]. Although the high
burden of COPD and the HIV disease is clearly demon-
strated, to the best of our knowledge, there is a lack of
summary and meta-analysis data on the epidemiology of
COPD in the global HIV-infected population to date.
We hereby present the protocol for a systematic re-
view and meta-analysis to summarize existing data on
the prevalence, incidence, and risk factors of COPD in
the global HIV-infected population.
Review questions
1) What is the prevalence of COPD in the global
HIV-infected population?
2) What is the incidence of COPD in the global
HIV-infected population?
3) Is the prevalence or incidence of COPD higher in
the global HIV-infected population compared to
general population?
4) What are the factors associated with COPD in the
global HIV-infected population?
Objectives
To respond to the review questions, a systematic-review
and meta-analysis will be conducted. The objectives will
be:
1) To synthetize the prevalence of COPD among the
global HIV-infected population;
2) To synthetize the incidence of COPD among the
global HIV-infected population;
3) To compare the prevalence and incidence of COPD
in the global HIV-infected population to those in the
general population;
4) To synthetize data on factors associated with COPD
in the global HIV-infected population.
Methods and design
Centre for Reviews and Dissemination recommendations
will be used as guidelines to conduct this review [11].
The guidelines for meta-analyses and systematic reviews
of Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) will serve as the template for
reporting the present review [12]. For the present proto-
col, the PRISMA for protocol was used for the reporting
[13]. An additional file shows the PRISMA for protocol
checklist [see Additional file 1]. This review protocol is
registered in the PROSPERO International Prospective
Register of systematic reviews, registration number
CRD42016052639.
Criteria for considering studies for review
Inclusion criteria
1) Observational studies (cross-sectional, case-control,
or cohort studies) reporting the prevalence, incidence,
and factors associated with COPD among HIV-
infected people and/or reporting the prevalence and/
or incidence of COPD in both HIV-infected and
general populations; or having enough data to
compute these estimates.
2) All published and unpublished studies reported from
inception to December 31st, 2016 will be
considered. Papers in English and French will be
considered for the present review regardless of
geographical limitation.
Exclusion criteria
1) Studies in subgroups of participants selected on the
basis of the presence of COPD.
2) Case series, reviews, letters, commentaries, and
editorials.
3) Studies lacking primary data and/or explicit method
description.
4) Studies that are limited to other specific groups or
populations like people with other respiratory
chronic diseases.
5) Duplicate reports. The most comprehensive and
up-to-date version will be considered for this review.
6) Studies that it will not be possible to have full text
even after contacting authors.
Search strategy for identifying relevant studies
The search strategy will be implemented in two stages:
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Bibliographic database search
A comprehensive and exhaustive search of PubMed/Med-
line, and Scopus will be performed to identify all relevant
articles published on COPD among HIV-infected people,
and the general population from inception to December
31st, 2016, without any language restriction. A search
strategy based on the combination of relevant terms will
be applied. The main search strategy that will use in
PubMed/Medline is shown in Table 1.
Searching other sources
A manual search to scan the reference lists of eligible pa-
pers and other relevant review articles will be conducted.
Selection of studies for inclusion in the review
Two investigators will independently identify articles
and sequentially screen their titles and abstracts for eligi-
bility. Full texts of articles deemed potentially eligible
will be acquired. These investigators will further inde-
pendently assess the full text of each study for eligibility
and consensually retain studies to be included. Disagree-
ments when existing will be solved by a third investiga-
tor. A screening guide will be used to ensure that the
selection criteria are reliably applied by all investigators.
Studies selection will be managed using EndNote X7.
Data extraction and management
Two investigators will extract data pertaining to:
1) Author details: name of first author and publication
year;
2) Study characteristics: country, region, study design,
setting, data source, sampling method, sample size,
total person duration of follow-up, data collection
period, and response rate;
3) Participants’ characteristics: age, gender, HIV related
data (time since diagnosis, severity of the disease,
antiretroviral (ART) regimens, and duration of
treatment);
4) COPD characteristics: diagnostic criteria used,
prevalence, incidence, associated factors, number of
participants tested and diagnosed with COPD overall,
and by subgroup of interest like level of urbanization,
gender, tobacco smoking, and ART regimens.
Where only primary data (sample size and number of
outcomes) will be provided, these data will be used to cal-
culate the prevalence or incidence estimates. Data will be
extracted using a preconceived, piloted, and standardized
data abstraction form. Disagreements between investiga-
tors will be reconciled through discussion and consensus,
or arbitration by a third investigator whenever necessary.
In case of multinational studies, the results will be sepa-
rated to show the estimate within individual countries.
When it will not be possible to disaggregate the data by
country, the study will be presented as one, and the coun-
tries in which the study was done will be shown.
Appraisal of the quality of included studies
The Newcastle-Ottawa Scale (NOS) will be used to
evaluate the methodological quality of case control and
cohort studies included in this review. An additional file
shows the NOS in detail [see Additional file 2] [14]. An
adapted version of this NOS will be used for cross-
sectional studies. These instruments will be used to also
make an assessment of the risk of bias affecting study
findings. There is no validation study that provides a
cut-off score for rating low-quality studies; at priori, we
will arbitrarily consider 0–3, 4–6, and 7–9 stars as high,
moderate, and low risk of bias respectively.
Table 1 PubMed search strategy for identifying studies
Search Query
#1 (“pulmonary disease, chronic obstructive”[MeSH Terms] OR (“pulmonary”[All Fields] AND “disease”[All Fields] AND “chronic”[All Fields]
AND “obstructive”[All Fields]) OR “chronic obstructive pulmonary disease”[All Fields] OR (“chronic”[All Fields] AND “obstructive”[All Fields]
AND “pulmonary”[All Fields] AND “disease”[All Fields])) OR (“pulmonary disease, chronic obstructive”[MeSH Terms] OR (“pulmonary”[All Fields]
AND “disease”[All Fields] AND “chronic”[All Fields] AND “obstructive”[All Fields]) OR “chronic obstructive pulmonary disease”[All Fields] OR
“copd”[All Fields]) OR (“pulmonary disease, chronic obstructive”[MeSH Terms] OR (“pulmonary”[All Fields] AND “disease”[All Fields] AND
“chronic”[All Fields] AND “obstructive”[All Fields]) OR “chronic obstructive pulmonary disease”[All Fields] OR (“chronic”[All Fields] AND
“obstructive”[All Fields] AND “airway”[All Fields] AND “disease”[All Fields]) OR “chronic obstructive airway disease”[All Fields]) OR (“pulmonary
disease, chronic obstructive”[MeSH Terms] OR (“pulmonary”[All Fields] AND “disease”[All Fields] AND “chronic”[All Fields] AND “obstructive
”[All Fields]) OR “chronic obstructive pulmonary disease”[All Fields] OR “coad”[All Fields]) OR (“pulmonary disease, chronic obstructive”[MeSH
Terms] OR (“pulmonary”[All Fields] AND “disease”[All Fields] AND “chronic”[All Fields] AND “obstructive”[All Fields]) OR “chronic obstructive
pulmonary disease”[All Fields] OR (“chronic”[All Fields] AND “obstructive”[All Fields] AND “lung”[All Fields] AND “disease”[All Fields]) OR
“chronic obstructive lung disease”[All Fields]) OR (airway[All Fields] AND flow[All Fields] AND obstruction[All Fields]) OR (chronic[All Fields]
AND airway[All Fields] AND flow[All Fields] AND obstruction[All Fields]) OR (“bronchitis, chronic”[MeSH Terms] OR (“bronchitis”[All Fields]
AND “chronic”[All Fields]) OR “chronic bronchitis”[All Fields] OR (“chronic”[All Fields] AND “bronchitis”[All Fields])) OR (“pulmonary
emphysema”[MeSH Terms] OR (“pulmonary”[All Fields] AND “emphysema”[All Fields]) OR “pulmonary emphysema”[All Fields])
#2 (“hiv”[MeSH Terms] OR “hiv”[All Fields]) OR (“acquired immunodeficiency syndrome”[MeSH Terms] OR (“acquired”[All Fields] AND
“immunodeficiency”[All Fields] AND “syndrome”[All Fields]) OR “acquired immunodeficiency syndrome”[All Fields] OR “aids”[All Fields])
#3 #1 AND #2
#4 #3 Limits: from inception to 2016/12/31
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Data synthesis including assessment of heterogeneity
Data will be analyzed using Stata software (Stata Corp V.13,
Texas, USA). Unadjusted prevalence/incidence and stand-
ard errors of hypertension will be recalculated based on the
information of crude numerators and denominators pro-
vided by individual studies. To keep the effect of studies
with extremely small or extremely large prevalence esti-
mates on the overall estimate to a minimum, the variance
of the study-specific prevalence/incidence will be stabilized
with the Freeman-Tukey single arc-sine transformation be-
fore pooling the data with the random-effects meta-analysis
model [15]. Heterogeneity will be evaluated by the chi-
squared test on Cochrane’s Q statistic [16], which will be
quantified by I-squared values, assuming that I-squared
values of 25, 50, and 75% being representative of low,
medium, and high heterogeneity, respectively [17]. When
substantial heterogeneity will be detected, we will perform
a subgroup analysis to investigate the possible sources of
heterogeneity using the following grouping variables: age
group, sex, study setting (rural vs urban), geographical area,
tobacco consumption status (current smokers, former
smokers, and never smoked), ART regimens, and study
quality. Additionally, we will report estimates after adjust-
ment on publication bias using the trim-and-fill method
[18]. We will assess inter-rater agreement between investi-
gators for study inclusion, data extraction, and methodo-
logical quality assessment using Kappa Cohen’s coefficient
[19]. We presume that the reporting of factors associated
with COPD will present high heterogeneity. If it is the case,
we will summarize the findings in a narrative format.
Assessment of reporting biases
Symmetry of funnel plots and Egger’s test will be done
to assess the presence of publication and selective
reporting bias [20]. A p value < 0.10 will be considered
indicative of statistically significant publication bias.
Potential amendments
We do not intend to make any amendments to the
protocol, to avoid the possibility of outcome reporting
bias. Any amendments during review process will be re-
ported transparently.
Discussion
The overarching goal of this review is to inform policy-
makers on the magnitude of COPD in HIV infection and
to provide accurate data that can underpin effective inter-
ventions for optimizing their detection and management.
In this context, we plan to conduct this review with the
aim of estimating the burden of this condition in this
population, there is a need of summarized and global data
on the topic. We hope that this review will serve to draw
attention and raise awareness on this growing concern. To
the best of our knowledge, this will be the first systematic
review and meta-analysis which aims to estimate the glo-
bal prevalence, incidence, and risk factors of COPD in
HIV-infected people. This review would be limited by the
impossibility to disaggregate data between patients on
ART and those naïve of ART. Another possible limitation
could be the predominance of hospital-based studies lim-
iting the generalizability of findings.
The current study is based on data already corrected
and as such ethics is not a requirement. The final report
of the systematic review in the form of scientific paper
will be published in peer-reviewed journals. Findings will
further be presented at conferences and be submitted to
relevant health authorities. We also plan to update the
review in future to monitor changes and to guide health
service and policy solutions.
Additional files
Additional file 1: Preferred Reporting Items for Systematic Review and
Meta-Analysis for protocol checklist. (DOCX 56 kb)
Additional file 2: Newcastle-Ottawa quality assessment scale. (PDF 135 kb)
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